JP2000504579A - 高等真核細胞の形質移入のための組成物 - Google Patents
高等真核細胞の形質移入のための組成物Info
- Publication number
- JP2000504579A JP2000504579A JP9528984A JP52898497A JP2000504579A JP 2000504579 A JP2000504579 A JP 2000504579A JP 9528984 A JP9528984 A JP 9528984A JP 52898497 A JP52898497 A JP 52898497A JP 2000504579 A JP2000504579 A JP 2000504579A
- Authority
- JP
- Japan
- Prior art keywords
- egla
- composition according
- peptide
- composition
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19605548A DE19605548A1 (de) | 1996-02-15 | 1996-02-15 | Zusammensetzung für die Transfektion höherer eukaryotischer Zellen |
| DE19605548.2 | 1996-02-15 | ||
| PCT/EP1997/000649 WO1997030170A1 (de) | 1996-02-15 | 1997-02-13 | Zusammensetzung für die transfektion höherer eukaryotischer zellen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2000504579A true JP2000504579A (ja) | 2000-04-18 |
| JP2000504579A5 JP2000504579A5 (https=) | 2004-11-18 |
Family
ID=7785445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9528984A Abandoned JP2000504579A (ja) | 1996-02-15 | 1997-02-13 | 高等真核細胞の形質移入のための組成物 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0900281A1 (https=) |
| JP (1) | JP2000504579A (https=) |
| CA (1) | CA2246227A1 (https=) |
| DE (1) | DE19605548A1 (https=) |
| MX (1) | MX9805507A (https=) |
| WO (1) | WO1997030170A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2766705B1 (fr) * | 1997-07-30 | 2001-05-25 | Biovector Therapeutics | Complexe particulaire de charge globale neutre ou negative forme d'une vesicule cationique ou neutre et d'une substance biologiquement active anionique, leur preparation et leur utilisation |
| FR2766706B1 (fr) * | 1997-07-30 | 2001-05-25 | Biovector Therapeutics Sa | Complexes particulaires stables de charge globale neutre ou negative de structure multilamellaire composes par au moins une substance biologiquement active globalement anionique et un constituant cationique, leur preparation et utilisation |
| GB9918670D0 (en) | 1999-08-06 | 1999-10-13 | Celltech Therapeutics Ltd | Biological product |
| GB0120022D0 (en) * | 2001-08-16 | 2001-10-10 | Photobiotics Ltd | Conjugate |
| ES2557382T3 (es) | 2010-07-06 | 2016-01-25 | Glaxosmithkline Biologicals Sa | Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN |
| EP2591114B1 (en) | 2010-07-06 | 2016-06-08 | GlaxoSmithKline Biologicals SA | Immunisation of large mammals with low doses of rna |
| ES2646669T3 (es) | 2010-07-06 | 2017-12-14 | Glaxosmithkline Biologicals Sa | Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN |
| LT4226941T (lt) | 2010-08-31 | 2025-01-10 | Glaxosmithkline Biologicals Sa | Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui |
| WO2012051211A2 (en) | 2010-10-11 | 2012-04-19 | Novartis Ag | Antigen delivery platforms |
| EP2729165B1 (en) | 2011-07-06 | 2017-11-08 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
| EP4115875A1 (en) | 2011-07-06 | 2023-01-11 | GlaxoSmithKline Biologicals S.A. | Liposomes having useful n:p ratio for delivery of rna molecules |
| WO2013051718A1 (ja) | 2011-10-07 | 2013-04-11 | 国立大学法人三重大学 | キメラ抗原受容体 |
| WO2017024318A1 (en) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses |
| US11052111B2 (en) | 2015-12-08 | 2021-07-06 | Chimera Bioengineering, Inc. | Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses |
| CN112481217A (zh) | 2016-09-01 | 2021-03-12 | 嵌合体生物工程公司 | Gold优化的car t-细胞 |
| JP7227912B2 (ja) | 2017-02-08 | 2023-02-24 | ダナ-ファーバー キャンサー インスティテュート,インコーポレイテッド | キメラ抗原受容体の調節 |
| WO2019217253A1 (en) | 2018-05-07 | 2019-11-14 | Children's Hospital Medical Center | Chimeric polypeptides, nucleic acid molecules, cells, and related methods |
| CN114007643A (zh) | 2019-04-19 | 2022-02-01 | 中外制药株式会社 | 识别抗体改变部位的嵌合受体 |
| WO2020246563A1 (ja) | 2019-06-05 | 2020-12-10 | 中外製薬株式会社 | 抗体切断部位結合分子 |
| CN116194124A (zh) | 2020-07-31 | 2023-05-30 | 中外制药株式会社 | 包含表达嵌合受体的细胞的药物组合物 |
| CN116997654A (zh) | 2021-03-17 | 2023-11-03 | 第一三共株式会社 | 编码抗乙酰胆碱受体自身抗体的嵌合受体的基因 |
| WO2022214887A1 (en) | 2021-04-08 | 2022-10-13 | Phosphogam, Llc | Methods and compositions for enhancing the cytotoxicity of gamma/delta-t cells |
| EP4650450A1 (en) | 2023-01-12 | 2025-11-19 | Yamaguchi University | Feline anti-pd-1 antibody |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ244306A (en) * | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
| US5578475A (en) * | 1993-07-12 | 1996-11-26 | Life Technologies, Inc. | Composition and methods for transfecting eukaryotic cells |
| FR2714830B1 (fr) * | 1994-01-10 | 1996-03-22 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| US5928944A (en) * | 1994-02-04 | 1999-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Method of adenoviral-medicated cell transfection |
| EP0874910A4 (en) * | 1995-06-07 | 1999-04-21 | Life Technologies Inc | ENHANCED CATIONIC LIPID TRANSFECTION BY PEPTIDES |
| IL115199A (en) * | 1995-09-07 | 2005-05-17 | Opperbas Holding Bv | Composition comprising a polynucleic acid molecule in a liposome and method using said composition |
-
1996
- 1996-02-15 DE DE19605548A patent/DE19605548A1/de not_active Ceased
-
1997
- 1997-02-13 WO PCT/EP1997/000649 patent/WO1997030170A1/de not_active Ceased
- 1997-02-13 EP EP97904426A patent/EP0900281A1/de not_active Withdrawn
- 1997-02-13 CA CA002246227A patent/CA2246227A1/en not_active Abandoned
- 1997-02-13 JP JP9528984A patent/JP2000504579A/ja not_active Abandoned
-
1998
- 1998-07-07 MX MX9805507A patent/MX9805507A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2246227A1 (en) | 1997-08-21 |
| DE19605548A1 (de) | 1997-09-04 |
| MX9805507A (es) | 1998-11-29 |
| EP0900281A1 (de) | 1999-03-10 |
| WO1997030170A1 (de) | 1997-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2000504579A (ja) | 高等真核細胞の形質移入のための組成物 | |
| JP3525393B2 (ja) | 脂質及び例えばリポソーム中でのその使用 | |
| AU738083B2 (en) | Cationic amphiphile/ DNA complexes | |
| JP3925815B2 (ja) | 細胞に遺伝子を運搬するための多機能分子複合体 | |
| EP0799059B1 (en) | Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules | |
| US7507859B2 (en) | Functional synthetic molecules and macromolecules for gene delivery | |
| US6756054B1 (en) | Polycationic sterol derivatives as transfection agents | |
| US5719131A (en) | Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules | |
| JP2001517939A (ja) | ペプチドによって増強されるトランスフェクション | |
| AU731503B2 (en) | Cationic amphiphile compositions for intracellular delivery of therapeutic molecules | |
| WO1998002190A9 (en) | Cationic amphiphile/dna complexes | |
| JPH11506935A (ja) | ペプチド増強カチオン脂質トランスフェクション | |
| FR2759382A1 (fr) | Nouveaux composes et compositions les contenant utilisables pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique | |
| CZ147398A3 (cs) | Nová transfekční činidla a jejich farmaceutická použití | |
| CN101094691A (zh) | 载体 | |
| WO1998043994A1 (en) | Cationic amphiphiles for intracellular delivery of therapeutic molecules | |
| Zhang et al. | Hybrids of nonviral vectors for gene delivery | |
| JP2009542582A (ja) | 生物活性物質を細胞に送達するための物質および複合体 | |
| JP2005515990A (ja) | 化合物 | |
| WO1999002190A1 (en) | Organ-specific targeting of cationic amphiphile/retinoblastoma encoding dna complexes for gene therapy | |
| US6331524B1 (en) | Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy | |
| EP1007003A1 (en) | Cationic amphiphile compositions for intracellular delivery of therapeutic molecules | |
| WO1998050416A1 (en) | Cationic amphiphiles containing multiple steroid lipophilic groups | |
| EP4480943A1 (en) | New class of lipids for delivering active ingredients into cells | |
| WO2009109996A2 (en) | Novel cationic amphiphiles with quinic acid head-groups for dna vaccination |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040212 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040212 |
|
| A762 | Written abandonment of application |
Free format text: JAPANESE INTERMEDIATE CODE: A762 Effective date: 20040915 |